Practiceby Lab 10 Get started ›
Crossfire

For early Alzheimer's disease, should the diet go high fat or very low fat?

What the experts say

Christopher M. PalmerMD · psychiatrist, McLean Hospital and Harvard Medical School

A ketogenic diet, high fat and very low carbohydrate, is worth asking a clinician about.

What it rests onA single case report on which he is last author: one patient with Down syndrome and Alzheimer's disease moved to under 20 grams of carbohydrate a day at 70 to 80 percent of calories from fat, with daily fingerstick ketones of 0.8 to 3.0 mmol/L. Her daily-living score rose from 34 to 57 of 78, 6 to 10 weekly seizures stopped within two weeks, and all medications were discontinued by six months. The authors state the competing explanation themselves: the gain may have followed from seizure control rather than from any effect on Alzheimer's pathology. n equals 1, and the paper's first author sells ketogenic books and products, disclosed in print.

Source: pmc.ncbi.nlm.nih.gov ↗
Dean Michael OrnishMD · internal medicine and cardiovascular disease; founder and president, Preventive Medicine Research Institute

An intensive multidomain lifestyle programme built on a whole-food plant-based diet at 14 to 18 percent fat is worth asking a neurologist about.

What it rests onA 1:1 randomised controlled trial, 51 patients with MCI or early dementia due to Alzheimer's, 20 weeks against a wait-list control: CGIC p=0.001, CDR-SB p=0.032, CDR Global p=0.037, ADAS-Cog borderline at p=0.053, plasma amyloid beta 42/40 ratio up in the intervention arm and down in controls (p=0.003). Read his own limitations before quoting him: the intervention bundles fifteen or more components including supervised Zoom sessions, delivered meals, exercise, stress management, a support group and eight supplements, so it supports one claim about the package and none about the diet alone. He and a co-author hold equity in Ornish Lifestyle Medicine; a further co-author co-founded the company supplying an optional device in the protocol.

Source: pmc.ncbi.nlm.nih.gov ↗

Overview

Both sides address people already diagnosed with early Alzheimer's or MCI, so the populations genuinely overlap, which is rarer than it sounds.

What does not match is the evidence weight: a randomised controlled trial of a fifteen-component package against a single case report of a diet, in a patient with Down syndrome and comorbid seizures. Neither side licenses a general-population dietary claim, and both amount to the same instruction: ask a clinician.

Where they agree

Both hold that diet and lifestyle can change the course of early Alzheimer's rather than only its comfort, which is itself a minority position in the field. Both route the decision to a clinician rather than to a checklist. Both carry commercial interests disclosed in print by their own hand. And neither claims a cure.

What would settle it

A trial that separates the diet from the package on Ornish's side, and anything beyond n equals 1 on Palmer's: a controlled trial of ketogenic therapy in Alzheimer's with seizure status as a covariate would address the competing explanation his own co-authors raised. A head-to-head of the two macronutrient directions in the same population does not exist and would settle more than either side can alone.

Practice does not pick a winner here

You do, and your call is dated, kept, and yours to change. Follow the people you already trust and what they publish turns into a short daily practice.

Get started

Free to sign up and use. We do not ask for a card.